[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$ff4skWTDNiPrUp2AJjrDgNvSCX6YM1MPvfo2okjjPnAg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Chongqing University Cancer Hospital",[4],43,false,23,1,22657,16,21,[14,17,20,23,26,28,30,32],{"name":15,"count":16},"Cervical Cancer",8,{"name":18,"count":19},"Locally Advanced Cervical Cancer",6,{"name":21,"count":22},"Ovarian Cancer",5,{"name":24,"count":25},"Nasopharyngeal Carcinoma",2,{"name":27,"count":25},"Nasopharyngeal Cancinoma (NPC)",{"name":29,"count":25},"Non-small Cell Lung Cancer",{"name":31,"count":9},"Nasopharyngeal Carcinoma by AJCC V8 Stage",{"name":33,"count":9},"Radiotherapy",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04409860","The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer","2024-04","Paclitaxel, Cisplatin",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04830267","The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R\u002FM NPC","2024-08-01","Camrelizumab",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05551208","Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi","2024-08-30","fluzopanib and bevacizumab",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT05687851","Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer","2024-12-30","Cadonilimab（AK104）",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06786780","Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids","2025-06-01","Drug: Cisplatin",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07217600","Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy","2026-03","Ondansetron orodispersible film once",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06059261","Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","2027-02-01","Envafolimab and recombinant human endostatin combined with chemoradiotherapy",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT05799469","Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer","2027-05-31","Envafolimab",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07425795","Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","2027-12-31","Tislelizumab Combined With Chemotherapy",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07543848","A Prospective, Multicenter, Single-Arm Phase II Exploratory Study of Serplulimab Combined With Oncolytic Virus H101, Short-Course Radiotherapy, and XELOX Chemotherapy as Total Neoadjuvant Treatment for Locally Advanced (cT1-3N0M0) Rectal Cancer","2028-12-31","Serplulimab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,119,137,162,194,214,236,254,279,300,324,345,366,390,408,426,447,485,507,533,556,574,599,628,646,664,682,709,735,753],{"intervention":64,"totalTrials":9,"cells":94},{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":117},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":9,"soonestReadout":63},[106],{"nctId":61,"briefTitle":62,"status":107,"phases":108,"primaryCompletion":63,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":115},"RECRUITING",[90],"2026-04","2025-03-25",60,[113,114],"Radiotherapy-induced Nausea and Vomiting (RINV)","Pediatric Cancer",[64,116],"Ondansetron orodispersible film twice",{"trials":118,"activeCount":97},[],{"intervention":116,"totalTrials":9,"cells":120},{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":125,"PHASE3":127,"PHASE4":129,"NA":135},{"trials":122,"activeCount":97},[],{"trials":124,"activeCount":97},[],{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":97},[],{"trials":130,"activeCount":9,"soonestReadout":63},[131],{"nctId":61,"briefTitle":62,"status":107,"phases":132,"primaryCompletion":63,"completion":109,"start":110,"enrollment":111,"conditions":133,"interventions":134},[90],[113,114],[64,116],{"trials":136,"activeCount":97},[],{"intervention":138,"totalTrials":9,"cells":139},"metronomic adjuvant chemotherapy with capecitabine",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":158,"NA":160},{"trials":141,"activeCount":97},[],{"trials":143,"activeCount":97},[],{"trials":145,"activeCount":97},[],{"trials":147,"activeCount":9,"soonestReadout":153},[148],{"nctId":149,"briefTitle":150,"status":151,"phases":152,"primaryCompletion":153,"completion":153,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NCT07248670","Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC","ACTIVE_NOT_RECRUITING",[89],"2031-12-31","2025-10-04",252,[27],[138],{"trials":159,"activeCount":97},[],{"trials":161,"activeCount":97},[],{"intervention":44,"totalTrials":25,"cells":163},{"EARLY_PHASE1":164,"PHASE1":166,"PHASE2":168,"PHASE3":188,"PHASE4":190,"NA":192},{"trials":165,"activeCount":97},[],{"trials":167,"activeCount":97},[],{"trials":169,"activeCount":9,"soonestReadout":43},[170,182],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT05213884","The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC","COMPLETED",[88],"2026-02-08","2022-01-01",39,[179],"Head and Neck Squamous Cell Carcinoma",[44,181],"Concurrent cisplatin chemotherapy",{"nctId":41,"briefTitle":42,"status":107,"phases":183,"primaryCompletion":43,"completion":184,"start":185,"enrollment":177,"conditions":186,"interventions":187},[88],"2026-08-01","2021-03-01",[24],[44],{"trials":189,"activeCount":97},[],{"trials":191,"activeCount":97},[],{"trials":193,"activeCount":97},[],{"intervention":69,"totalTrials":9,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":208,"PHASE4":210,"NA":212},{"trials":197,"activeCount":97},[],{"trials":199,"activeCount":97},[],{"trials":201,"activeCount":9,"soonestReadout":68},[202],{"nctId":66,"briefTitle":67,"status":107,"phases":203,"primaryCompletion":68,"completion":68,"start":204,"enrollment":205,"conditions":206,"interventions":207},[88],"2026-02-09",30,[24],[69],{"trials":209,"activeCount":97},[],{"trials":211,"activeCount":97},[],{"trials":213,"activeCount":97},[],{"intervention":74,"totalTrials":9,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":230,"PHASE4":232,"NA":234},{"trials":217,"activeCount":97},[],{"trials":219,"activeCount":97},[],{"trials":221,"activeCount":9,"soonestReadout":73},[222],{"nctId":71,"briefTitle":72,"status":223,"phases":224,"primaryCompletion":73,"completion":78,"start":225,"enrollment":226,"conditions":227,"interventions":228},"NOT_YET_RECRUITING",[88],"2023-05-01",36,[18],[74,229],"Cisplatin",{"trials":231,"activeCount":97},[],{"trials":233,"activeCount":97},[],{"trials":235,"activeCount":97},[],{"intervention":229,"totalTrials":9,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":242,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":239,"activeCount":97},[],{"trials":241,"activeCount":97},[],{"trials":243,"activeCount":9,"soonestReadout":73},[244],{"nctId":71,"briefTitle":72,"status":223,"phases":245,"primaryCompletion":73,"completion":78,"start":225,"enrollment":226,"conditions":246,"interventions":247},[88],[18],[74,229],{"trials":249,"activeCount":97},[],{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":97},[],{"intervention":255,"totalTrials":9,"cells":256},"Enlonstobart",{"EARLY_PHASE1":257,"PHASE1":259,"PHASE2":261,"PHASE3":273,"PHASE4":275,"NA":277},{"trials":258,"activeCount":97},[],{"trials":260,"activeCount":97},[],{"trials":262,"activeCount":9,"soonestReadout":267},[263],{"nctId":264,"briefTitle":265,"status":223,"phases":266,"primaryCompletion":267,"completion":267,"start":268,"enrollment":269,"conditions":270,"interventions":272},"NCT06981858","A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer",[88],"2029-02-01","2025-05-15",34,[271],"LOCALLY ADVANCED CERVICAL CANCERS",[255],{"trials":274,"activeCount":97},[],{"trials":276,"activeCount":97},[],{"trials":278,"activeCount":97},[],{"intervention":54,"totalTrials":9,"cells":280},{"EARLY_PHASE1":281,"PHASE1":283,"PHASE2":285,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":282,"activeCount":97},[],{"trials":284,"activeCount":97},[],{"trials":286,"activeCount":9,"soonestReadout":53},[287],{"nctId":51,"briefTitle":52,"status":107,"phases":288,"primaryCompletion":53,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},[88],"2026-12","2022-12-29",33,[18],[54],{"trials":295,"activeCount":97},[],{"trials":297,"activeCount":97},[],{"trials":299,"activeCount":97},[],{"intervention":59,"totalTrials":9,"cells":301},{"EARLY_PHASE1":302,"PHASE1":304,"PHASE2":306,"PHASE3":318,"PHASE4":320,"NA":322},{"trials":303,"activeCount":97},[],{"trials":305,"activeCount":97},[],{"trials":307,"activeCount":9,"soonestReadout":58},[308],{"nctId":56,"briefTitle":57,"status":309,"phases":310,"primaryCompletion":58,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":317},"ENROLLING_BY_INVITATION",[88],"2026-06-01","2023-01-01",50,[315,316],"Cervical Cancer Treated with Pelvic Radiotherapy","Cervical Cancers",[59],{"trials":319,"activeCount":97},[],{"trials":321,"activeCount":97},[],{"trials":323,"activeCount":97},[],{"intervention":79,"totalTrials":9,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":327,"activeCount":97},[],{"trials":329,"activeCount":97},[],{"trials":331,"activeCount":9,"soonestReadout":78},[332],{"nctId":76,"briefTitle":77,"status":107,"phases":333,"primaryCompletion":78,"completion":334,"start":335,"enrollment":226,"conditions":336,"interventions":338},[88],"2028-07-31","2025-10-10",[337],"Extensive Stage Small Cell Lung Cancer (ES-SCLC)",[79],{"trials":340,"activeCount":97},[],{"trials":342,"activeCount":97},[],{"trials":344,"activeCount":97},[],{"intervention":49,"totalTrials":9,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":360,"PHASE4":362,"NA":364},{"trials":348,"activeCount":97},[],{"trials":350,"activeCount":97},[],{"trials":352,"activeCount":9,"soonestReadout":48},[353],{"nctId":46,"briefTitle":47,"status":107,"phases":354,"primaryCompletion":48,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},[88],"2029-08-30","2022-08-15",42,[21],[49],{"trials":361,"activeCount":97},[],{"trials":363,"activeCount":97},[],{"trials":365,"activeCount":97},[],{"intervention":84,"totalTrials":9,"cells":367},{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":384,"PHASE4":386,"NA":388},{"trials":369,"activeCount":97},[],{"trials":371,"activeCount":97},[],{"trials":373,"activeCount":9,"soonestReadout":83},[374],{"nctId":81,"briefTitle":82,"status":223,"phases":375,"primaryCompletion":83,"completion":83,"start":376,"enrollment":377,"conditions":378,"interventions":381},[88],"2026-05-01",20,[379,380],"Rectal Neoplasms","Rectal Adenocarcinoma",[84,382,383],"Oncolytic Virus H101","XELOX Chemotherapy",{"trials":385,"activeCount":97},[],{"trials":387,"activeCount":97},[],{"trials":389,"activeCount":97},[],{"intervention":382,"totalTrials":9,"cells":391},{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":393,"activeCount":97},[],{"trials":395,"activeCount":97},[],{"trials":397,"activeCount":9,"soonestReadout":83},[398],{"nctId":81,"briefTitle":82,"status":223,"phases":399,"primaryCompletion":83,"completion":83,"start":376,"enrollment":377,"conditions":400,"interventions":401},[88],[379,380],[84,382,383],{"trials":403,"activeCount":97},[],{"trials":405,"activeCount":97},[],{"trials":407,"activeCount":97},[],{"intervention":383,"totalTrials":9,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":411,"activeCount":97},[],{"trials":413,"activeCount":97},[],{"trials":415,"activeCount":9,"soonestReadout":83},[416],{"nctId":81,"briefTitle":82,"status":223,"phases":417,"primaryCompletion":83,"completion":83,"start":376,"enrollment":377,"conditions":418,"interventions":419},[88],[379,380],[84,382,383],{"trials":421,"activeCount":97},[],{"trials":423,"activeCount":97},[],{"trials":425,"activeCount":97},[],{"intervention":39,"totalTrials":9,"cells":427},{"EARLY_PHASE1":428,"PHASE1":430,"PHASE2":432,"PHASE3":434,"PHASE4":436,"NA":438},{"trials":429,"activeCount":97},[],{"trials":431,"activeCount":97},[],{"trials":433,"activeCount":97},[],{"trials":435,"activeCount":97},[],{"trials":437,"activeCount":97},[],{"trials":439,"activeCount":9,"soonestReadout":38},[440],{"nctId":36,"briefTitle":37,"status":107,"phases":441,"primaryCompletion":38,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},[91],"2029-04","2020-05-26",120,[15],[39],{"intervention":448,"totalTrials":25,"cells":449},"PEG-rhG-CSF",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":454,"PHASE3":466,"PHASE4":468,"NA":483},{"trials":451,"activeCount":97},[],{"trials":453,"activeCount":97},[],{"trials":455,"activeCount":97},[456],{"nctId":457,"briefTitle":458,"status":173,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":111,"conditions":463,"interventions":464},"NCT04542356","Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer",[88],"2021-01-26","2021-05-26","2018-08-01",[15],[448,465],"rhG-CSF",{"trials":467,"activeCount":97},[],{"trials":469,"activeCount":97},[470],{"nctId":471,"briefTitle":472,"status":473,"phases":474,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":479,"interventions":481},"NCT06026995","Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells","UNKNOWN",[90],"2024-01-01","2024-06-01","2022-03-01",174,[480],"Lymphoma",[448,482],"RhG-CSF",{"trials":484,"activeCount":97},[],{"intervention":482,"totalTrials":25,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":497,"PHASE4":499,"NA":505},{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":97},[],{"trials":492,"activeCount":97},[493],{"nctId":457,"briefTitle":458,"status":173,"phases":494,"primaryCompletion":460,"completion":461,"start":462,"enrollment":111,"conditions":495,"interventions":496},[88],[15],[448,465],{"trials":498,"activeCount":97},[],{"trials":500,"activeCount":97},[501],{"nctId":471,"briefTitle":472,"status":473,"phases":502,"primaryCompletion":475,"completion":476,"start":477,"enrollment":478,"conditions":503,"interventions":504},[90],[480],[448,482],{"trials":506,"activeCount":97},[],{"intervention":508,"totalTrials":9,"cells":509},"selinexor",{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":531},{"trials":511,"activeCount":97},[],{"trials":513,"activeCount":97},[],{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":97},[],{"trials":519,"activeCount":97},[520],{"nctId":521,"briefTitle":522,"status":473,"phases":523,"primaryCompletion":524,"completion":525,"start":526,"enrollment":527,"conditions":528,"interventions":530},"NCT05786989","Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma",[90],"2024-03-31","2024-09-30","2023-02-28",32,[529],"Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",[508],{"trials":532,"activeCount":97},[],{"intervention":534,"totalTrials":9,"cells":535},"Almonertinib",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":550,"PHASE4":552,"NA":554},{"trials":537,"activeCount":97},[],{"trials":539,"activeCount":97},[],{"trials":541,"activeCount":97},[542],{"nctId":543,"briefTitle":544,"status":473,"phases":545,"primaryCompletion":546,"completion":43,"start":185,"enrollment":313,"conditions":547,"interventions":549},"NCT04905550","Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC",[88],"2024-03-01",[548],"Non-Small Cell Lung Cancer (NSCLC)",[534],{"trials":551,"activeCount":97},[],{"trials":553,"activeCount":97},[],{"trials":555,"activeCount":97},[],{"intervention":181,"totalTrials":9,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[564],{"nctId":171,"briefTitle":172,"status":173,"phases":565,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":566,"interventions":567},[88],[179],[44,181],{"trials":569,"activeCount":97},[],{"trials":571,"activeCount":97},[],{"trials":573,"activeCount":97},[],{"intervention":575,"totalTrials":9,"cells":576},"Fluzoparib monotherapy or Fluzoparib with Camrelizumab",{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":593,"PHASE4":595,"NA":597},{"trials":578,"activeCount":97},[],{"trials":580,"activeCount":97},[],{"trials":582,"activeCount":97},[583],{"nctId":584,"briefTitle":585,"status":473,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":444,"conditions":590,"interventions":592},"NCT06055166","A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors",[88],"2024-11-30","2026-05-31","2023-11-01",[591],"PARP Inhibitor for Esophageal Squamous Cell Carcinoma",[575],{"trials":594,"activeCount":97},[],{"trials":596,"activeCount":97},[],{"trials":598,"activeCount":97},[],{"intervention":600,"totalTrials":9,"cells":601},"ThisCART19A",{"EARLY_PHASE1":602,"PHASE1":604,"PHASE2":606,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":603,"activeCount":97},[],{"trials":605,"activeCount":97},[],{"trials":607,"activeCount":97},[608],{"nctId":609,"briefTitle":610,"status":473,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT05776407","Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma",[87,88],"2024-05","2024-11","2023-05",12,[617],"Refractory or Relapsed B Cell Lymphoma",[600,619,620,621],"Fludarabine","Cyclophosphamide","Etoposide",{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":97},[],{"trials":627,"activeCount":97},[],{"intervention":619,"totalTrials":9,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":640,"PHASE4":642,"NA":644},{"trials":631,"activeCount":97},[],{"trials":633,"activeCount":97},[],{"trials":635,"activeCount":97},[636],{"nctId":609,"briefTitle":610,"status":473,"phases":637,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":638,"interventions":639},[87,88],[617],[600,619,620,621],{"trials":641,"activeCount":97},[],{"trials":643,"activeCount":97},[],{"trials":645,"activeCount":97},[],{"intervention":620,"totalTrials":9,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":649,"activeCount":97},[],{"trials":651,"activeCount":97},[],{"trials":653,"activeCount":97},[654],{"nctId":609,"briefTitle":610,"status":473,"phases":655,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":656,"interventions":657},[87,88],[617],[600,619,620,621],{"trials":659,"activeCount":97},[],{"trials":661,"activeCount":97},[],{"trials":663,"activeCount":97},[],{"intervention":621,"totalTrials":9,"cells":665},{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":676,"PHASE4":678,"NA":680},{"trials":667,"activeCount":97},[],{"trials":669,"activeCount":97},[],{"trials":671,"activeCount":97},[672],{"nctId":609,"briefTitle":610,"status":473,"phases":673,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":674,"interventions":675},[87,88],[617],[600,619,620,621],{"trials":677,"activeCount":97},[],{"trials":679,"activeCount":97},[],{"trials":681,"activeCount":97},[],{"intervention":683,"totalTrials":9,"cells":684},"Furmonertinib 160 mg, Q.D.",{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":686,"activeCount":97},[],{"trials":688,"activeCount":97},[],{"trials":690,"activeCount":97},[691],{"nctId":692,"briefTitle":693,"status":473,"phases":694,"primaryCompletion":695,"completion":696,"start":697,"enrollment":205,"conditions":698,"interventions":702},"NCT05548348","First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation",[88],"2023-12-31","2025-10-31","2022-09-26",[29,699,700,701],"EGFR G719X","EGFR L861Q","EGFR S768I",[683],{"trials":704,"activeCount":97},[],{"trials":706,"activeCount":97},[],{"trials":708,"activeCount":97},[],{"intervention":710,"totalTrials":9,"cells":711},"niraparib combined with brivanib",{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":716,"PHASE3":729,"PHASE4":731,"NA":733},{"trials":713,"activeCount":97},[],{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[718],{"nctId":719,"briefTitle":720,"status":473,"phases":721,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":726,"interventions":727},"NCT04395612","Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer",[88],"2022-04-01","2022-07-01","2020-05-08",38,[15],[710,728],"niraparib combined with toripalimab",{"trials":730,"activeCount":97},[],{"trials":732,"activeCount":97},[],{"trials":734,"activeCount":97},[],{"intervention":728,"totalTrials":9,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":747,"PHASE4":749,"NA":751},{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"trials":742,"activeCount":97},[743],{"nctId":719,"briefTitle":720,"status":473,"phases":744,"primaryCompletion":722,"completion":723,"start":724,"enrollment":725,"conditions":745,"interventions":746},[88],[15],[710,728],{"trials":748,"activeCount":97},[],{"trials":750,"activeCount":97},[],{"trials":752,"activeCount":97},[],{"intervention":754,"totalTrials":9,"cells":755},"transdermal fentanyl",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":766},{"trials":757,"activeCount":97},[],{"trials":759,"activeCount":97},[],{"trials":761,"activeCount":97},[],{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[],{"trials":767,"activeCount":97},[768],{"nctId":769,"briefTitle":770,"status":173,"phases":771,"primaryCompletion":772,"completion":695,"start":773,"enrollment":774,"conditions":775,"interventions":778},"NCT06369961","Correlation Between the Analgesic Effect of Fentanyl Transdermal Patches and Nutritional Status in Cancer Pain Patients",[],"2023-07-31","2023-03-01",151,[776,777],"Cancer Pain","Nutrition Disorders",[754]]